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A 45-year-old Caucasian male presented with a two-week history of jaundice and right-upper quadrant (RUQ) abdominal pain.
Transaminases and biliary enzymes were markedly elevated with hyperferritinemia and mildly elevated INR. Imaging tests showed
no signiﬁcant abnormality. He denied prescription or over-the-counter (OTC) medication use, but he had been taking at least
9 dietary supplements for 12 months. Other causes of liver disease were excluded. His supplements were discontinued, and his
liver-associated enzymes signiﬁcantly markedly improved over the next 6 weeks and remained normal after one year suggesting
supplement-induced hepatotoxicity. Due to the number of supplements, no speciﬁc agent could be identiﬁed as the primary cause
of his liver injury. This case illustrates the importance of inquiring and educating patients of the potential harmful risks of over-
the-counter medications and supplements.
1.Introduction
Over-the-counter (OTC) supplement use has increased in
the United States over the past decade, and sources estimate
that consumers can now choose from over 29,000 products
[1]. Dietary supplement-related hepatotoxicity, an under-
reported condition, is usually associated with minor liver-
associatedenzymeelevations[2].Wedescribeacaseofsevere
hepatotoxicity with jaundice and mild synthetic dysfunction
in a patient taking multiple dietary supplements.
2.Case
A previously healthy 45-year-old white male complained of
dull aching RUQ pain associated with nausea two weeks
prior to his initial presentation to primary care. The pain
was constant, nonradiating, and most intense two hours
after meals. The pain was followed by icterus, jaundice, and
generalized weakness, which progressively worsened over the
week. He had secondary anorexia over the symptomatic
period and had lost 20lbs over the previous two months. He
denied pruritus, easy bleeding/bruising, melena, abdominal
distention, mental status changes, increased somnolence,
diarrhea, or fever.
He initially reported taking only a few daily supplements
over the previous 12 months for the promotion of general
health. However, on further questioning, he admitted using
nine diﬀerent products many of which had been started one-
to-fourmonthspriortohissymptomonset(Table 1).Hehad
stopped all supplements intake after the development of his
symptoms.
Additional risk factors for secondary causes of liver
disease were negative to include a history of viral hepatitis,
blood product transfusion, intravenous drug abuse, multiple
sexual partners, and prescription medications. He consumed
two-to-three mixed drinks on social occasions and was not
a habitual alcohol consumer. He denied acetaminophen
use or the ingestion of wild mushrooms. He recently
vacationedwithhiswifeinPuertoRicothreemonthspriorto
presentationbutdeniedanyadditionalforeigntravel.Hehad
no family history of liver disease and denied any ill contacts.
His physical examination was only notable for jaundice,
scleral icterus, and mild RUQ abdominal tenderness on
deep palpation. Signiﬁcant presentation labs are as follows:
ALT 6409U/l, AST 3505U/l, alkaline phosphatase 269U/L,
total bilirubin 31mg/uL, conjugated bilirubin 18mg/dL,
prothrombin time 12.6sec, and INR 1.2. Iron studies were
ferritin 2641ng/mL, fasting iron 235ug/dL, TIBC 290ug/dL,2 Case Reports in Medicine
Table 1: Reported supplements in this case.
∗Mixture of ingredients without dosage listed
(1) Living Multi
Optimal Men’s Formula
Vitamin A, vitamin C, vitamin D, vitamin E, thiamine, riboﬂavin, niacin, vitamin B6, folic acid, vitamin B12,
biotin, pantothenic acid, calcium, iodine, iron, magnesium, zinc, selenium, copper, manganese, chromium,
molybdenum, potassium, boron, vanadium, choline, lycopene, lutein
(Natural Antioxidant Fruit and Veggie Blend, Poten-Zyme Sea Veggie Blend, Men’s Blend, Poten-Zyme Tonic
Mushroom Blend, Poten-Zyme Veggie Blend, Antioxidant Beverage and Spice Blend)
http://www.gardenoﬂifeusa.com/ProductsforLife/SUPPLEMENTS/LivingNutrients/LivingMultiMens/tabid/668/Default.aspx
4 per day in morning with breakfast
(2) Living Calcium Advanced
Bone Density Support Formula ∗
Vitamin D, riboﬂavin, vitamin B6, folic acid, vitamin B12, calcium, iron, magnesium, zinc, copper, manganese,
boron, vitamin K, betaine
(Bone Support Blend, Vital Mineral Matrix, Homocysteine Balance Complex)
http://www.gardenoﬂifeusa.com/ProductsforLife/SUPPLEMENTS/LivingNutrients/LivingCalciumAdvanced/tabid/666/Default.aspx
3 per day in morning for broken elbow
(3) Perfect Food
Super Green Formula Caplets
Vitamin A, vitamin C, calcium, iron
(Poten-Zyme Whole Food Matrix, Perfect Green Juice Blend, Perfect Protein Mineral Blend, Acerola Cherry
Extract, Perfect Veggie Juice Blend, Probiotic Blend)
http://www.gardenoﬂifeusa.com/ProductsforLife/SUPPLEMENTS/FoundationalNutrition/PerfectFood/tabid/654/Default.aspx
2 per day in morning
(4) FYI ULTRA
Ultimate Joint & Cartilage Formula
Selenium, glucosamine HCL
(Protective Tissue Response Blend, Antioxidant Cartilage Health Complex)
http://www.gardenoﬂifeusa.com/ProductsforLife/SUPPLEMENTS/ImmunitySupport/FYIULTRA/tabid/658/Default.aspx
3 per day in morning
(5) f¨ ucoThin
Concentrated fucoxanthin
(Xanthigen Proprietary Blend)
http://www.fucothin.com/FAQs/tabid/1160/Default.aspx
1 in morning and 1 in evening with meal “dietary supplement”
(6) Bone Strength Take Care
Vitamin D, calcium, magnesium, vanadium, vitamin K, strontium, silica, betaine
http://www.newchapter.com/products/bone-strength-take-care
2 per day in evening for broken elbow
(7) 4Total Nutrition
Individual ingredients not listed
http://www.genesistoday.com/genesis today products/4total nutrition.html
1 tablespoon mixed with juice in evening (stopped taking after 2 weeks, bad taste)
(8) POWER4
Individual ingredients not listed
http://www.genesistoday.com/genesis today products/power 4.html
1 tablespoon mixed with juice in morning “use this to drink down my vitamins”
(9) Ab-Solution Plus
Individual ingredients not listed
http://www.vyotech.com/products/absolutionplus/
Rub on stomach area once in the morning and in the evening
and % transferrin sat 81%. CBC was normal without
eosinophilia. Serum acetaminophen level was immeasurable
as the severe hyperbilirubinemia interfered with the assay.
The patient did not have any baseline liver enzymes for com-
parison. RUQ ultrasound and CT abdomen revealed mild
diﬀuse thickening of the gallbladder without cholelithiasis
or intra/extrahepatic ductal dilatation. The pancreas, liver,
portal veins, and spleen were otherwise normal.
Theworkupforothercausesof liver diseaseincludes IgM
anti-HAV, IgM anti-HBc, HbsAg, anti-HCV, ceruloplasmin,Case Reports in Medicine 3
(a) (b)
Figure 1: (a) Periportal triad inﬂammation (b) cholestasis and hepatocyte necrosis (zone 3) iron liver 321ug/g dry wt (400–2200), hepatic
iron index 0.1umoL/g/yr (<1.0).
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Figure 2: Followup labs at 6 weeks.
mitochondrial antibody, ANA, SPEP, and anti-LKM which
were negative/normal except for the presence of one het-
erozygous copy of the H63D mutation in the HFE gene and
a highly positive smooth muscle antibody of 32 (>30 highly
positive). Liver histopathology revealed mild periportal and
intraparenchymal chronic inﬂammation, including plasma
cells, with focal areas of acute inﬂammation and patchy
hepatocyte necrosis with moderately increased iron storage
(Ironliverdryweight321ug/g(400–2200)hepaticironindex
0.1umoL/g/yr (<1.0)) (Figure 1). Copper studies of liver
biopsy were not performed.
The liver biopsy was secondarily reviewed by the Armed
Forces Institute of Pathology that reported widespread zone
3 (centrilobular) conﬂuent necrosis and stromal collapse
with patchy portal inﬂammation and considerable bile stasis.
Their interpretation of the combined cholestatic and hepato-
cellular injury pattern was consistent with drug/supplement-
related hepatotoxicity. The ﬁndings were not consistent with4 Case Reports in Medicine
autoimmune hepatitis. At 6 weeks, the patient’s symptoms
had resolved. Repeat liver-associated enzymes had nearly
normalized (ALT-135U/L and total bilirubin-1.4mg/uL)
a n di r o ns t u d i e ss h o w e da%i r o ns a t u r a t i o no f5 2 %
and serum ferritin of 196ng/ml (Figure 2). At one year,
his liver enzymes were completely normal. To date, the
patient remains asymptomatic and continues to avoid OTC
supplements.
3. Discussion
Approximately 65% of the US population reports use of
complementary and alternative medical (CAM) therapies. In
1997, US consumers spent $46 billion on CAM therapies
and dietary supplements. Women and non-Hispanic whites
more frequently use alternative medicines compared to
males and other racial groups, respectively [1]. While many
explanations have been oﬀered for increased use of CAM
therapy, users generally view natural products as superior
and innocuous compared to traditional medications. These
consumers also often seek alternative treatments when they
are not satisﬁed with conventional treatment [3].
In 1994, the Dietary Supplement Health and Education
Act expanded the responsibilities of the Food and Drug
Administration (FDA) to include monitoring safety and
product information of CAM therapies [4]. Enforcement
of this regulation has proved problematic, as manufacturers
are still not required to register for FDA approval or prove
a product’s safety prior to marketing [4]. Content labeling
and product consistency remain variable, and adverse eﬀects
from these products are likely underreported.
Hepatotoxicity is common with both CAM and conven-
tional medication therapies, due to the liver’s primary role
in drug metabolism [2]. Medication-induced liver injury is
often grouped into types of injury based on biochemical
and histological abnormalities, and certain medications
have been classically associated with speciﬁc injury patterns
[5]. Our patient manifested a mixed liver injury pattern.
Our case is interesting in that our patient’s transaminases
were three-to-six times higher than those of other cases
reported in the medical literature [6]. The clinical and
laboratorypresentationrepresentsseverehepatotoxicitywith
mild synthetic dysfunction and rapid resolution, while many
cases in literature progress to acute liver failure.
Our patient was taking nine diﬀerent supplements
which comprised of over thirty individual ingredients
(Tables 1 and 2). He was also taking several supplements
which contained no ingredient description. All available
ingredients were reviewed for potential harm using the orig-
inal product’s manufacturer website, the consumer reports
from the US Food and Drug Administration, and annual
reports from the American Association of Poison Control
Center.Table 3 listscommonherbalremediesassociatedwith
hepatotoxicity [7, 8]. When comparing the patient’s list of
ingredients to the common toxins causing hepatotoxicity,
potential oﬀending agents include vitamin A, copper, iron,
and niacin. Unfortunately a speciﬁc contributing source
could not be ascertained, due to the large number of
Table 2: Summary of individual ingredients in supplements that
exceeded recommended daily allowance (RDA) in this case.
RDA% RDA Total
Vitamin A (IU) 416.67% 3000 12,500
Vitamin C (mg) 166.67% 90 150
Vitamin D (IU) 900.00% 200 1,800
Vitamin E (IU) 200.89% 22.4 45
Thiamine (B1) (mg) 375.00% 1.2 5
Riboﬂavin (B2) (mg) 1161.54% 1.3 15
Niacin (B3) (mg) 187.50% 16 30
Vitamin B6 (mg) 2384.62% 1.3 31
Folic acid (mcg) 200.00% 400 800
Vitamin B12 (mcg) 10333.33% 2.4 248
Biotin (mcg) 3000.00% 30 900
Pantothenic Acid (mg) 600.00% 5 30
Calcium (mg) 208.00% 1000 2,080
Iodine (mcg) 120.00% 150 180
Magnesium (mg) 153.10% 420 643
Zinc (mg) 163.64% 11 18
Selenium (mcg) 363.64% 55 200
Manganese (mg) 173.91% 2.3 4
Chromium (mcg) 571.43% 35 200
Molybdenum (mcg) 166.67% 45 75
Vitamin K (mcg) 170.83% 120 205
Table 3: Common herbal supplements associated with hepatotoxi-
city.
Herbal supplement induced hepatotoxicity
Pyrrolizidine alkaloids Ma-Huang
Germander Syo-saiko-to
Greater celandine Bajiaolian
Chaparral Borage
Atractylis gummifera Broom corn
Pennyroyal Callilepis
Mistletoe Margosa Oil
Kava Kava LipoKinetix
Camellia sinensis Hydroxycut
Jin Bu Huan HerbaLife
supplements involved and the unknown ingredients of a few
of the supplements. Our patient’s markedly elevated ferritin
and antismooth muscle antibodies were most likely due to
the supplement-induced acute liver injury. His increased
% iron saturation, interestingly, is secondary to his H63D
heterozygous mutation as his ferritin was normalized in
followup but the increased % iron saturation persisted.
The low hepatic iron weight and hepatic iron index ruled
out hemochromatosis. Autoimmune hepatitis was ruled out
clinically and conﬁrmed by the normalization of his liver
enzymes.
Treatment for supplement-induced hepatotoxicity con-
sists of prompt cessation of all supplement use. The develop-
ment of any encephalopathy or worsening of coagulopathyCase Reports in Medicine 5
requires an immediate referral to a medical center with
a liver transplantation service [9]. There are no conﬁr-
matory tests; however, appropriate evaluation to exclude
other underlying hereditary or acquired liver disease is
prudent. Clinical improvement occurs in most cases after
discontinuance of oﬀending agent, but liver injury may
worsen or follow a protracted recovery course of weeks
or months [9]. If patients develop acute fulminant hepatic
failure, important prognostic indicators include the degree
of encephalopathy, the patient’s age, prothrombin time, and
the cause of acute liver failure [9]. Given the absence of
encephalopathy, prompt normalization of his initial mild
protime elevation, and gradual recovery within weeks after
discontinuing his supplements, liver transplantation was
not considered in our patient. This case emphasizes the
importance of recognizing the widespread use of over-
the-counter supplements and herbal remedies. Health care
providers should inform their patients about the potentially
harmful risks of over-the-counter supplement use, particu-
larly hepatotoxicity. Providers should also be vigilant about
reporting any suspected supplement-related hepatotoxicity
to the FDA immediately.
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